Jeff Yass’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-66,400
| Closed | -$3.48M | – | 14493 |
|
|
2022
Q1 | $2.13M | Buy |
+66,400
| New | +$1.91M | ﹤0.01% | 5341 |
|
|
2019
Q4 | – | Sell |
-674
| Closed | -$11K | – | 10993 |
|
|
2019
Q3 | $11K | Buy |
+674
| New | +$12.9K | ﹤0.01% | 10015 |
|
|
2019
Q1 | – | Sell |
-371
| Closed | -$20K | – | 10188 |
|
|
2018
Q4 | $20K | Buy |
+371
| New | +$23.7K | ﹤0.01% | 8681 |
|
|
2017
Q4 | – | Sell |
-1,371
| Closed | -$85K | – | 10136 |
|
|
2017
Q3 | $85K | Sell |
1,371
-11,407
| -89% | -$669K | ﹤0.01% | 8416 |
|
|
2017
Q2 | $598K | Sell |
12,778
-897
| -7% | -$45.8K | ﹤0.01% | 6302 |
|
|
2017
Q1 | $837K | Buy |
13,675
+13,233
| +2,994% | +$769K | ﹤0.01% | 5510 |
|
|
2016
Q4 | $26K | Sell |
442
-156
| -26% | -$9.72K | ﹤0.01% | 9398 |
|
|
2016
Q3 | $44K | Buy |
+598
| New | +$46.2K | ﹤0.01% | 8162 |
|
|
2016
Q2 | – | Sell |
-1,504
| Closed | -$405K | – | 9569 |
|
|
2016
Q1 | $405K | Buy |
1,504
+1,144
| +318% | +$365K | ﹤0.01% | 6766 |
|
|
2015
Q4 | $216K | Buy |
+360
| New | +$244K | ﹤0.01% | 8295 |
|
Other funds holding SRRA
Jeff Yass's SRRA Position: Q2 2022 in Review
Jeff Yass sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 66,400 shares — an estimated $3.48M sold.
Jeff Yass first reported a position in SRRA in Q4 2015 and held it in 10 quarters. The position peaked at $2.13M in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.
- Jeff Yass reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
- Jeff Yass sold 66,400 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $3.48M.
- Jeff Yass first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2015 and held it in 10 quarters.
- Jeff Yass's Sierra Oncology, Inc. Common Stock position peaked at $2.13M in Q1 2022.
- 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.
Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.